Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised funding from the European Eurostars Programme to coordinate a two-year research project aimed at developing liposomes for vaccine and adjuvant delivery. The project, operating under the acronym LIPODEL, will have a total budget of €729,500.
The project’s main focus will be to enhance technologies in order to improve immune responses for preventive and curative purposes.Telormedix will coordinate three research teams to develop liposomes targeting monocytes and plasmacytoid pre-dendritic cells co-delivering TLR7 agonists for immunotherapy. LIPODEL liposomes will then be used to assemble a Group B Streptococcus vaccine candidate. The three additional research teams participating in the LIPODEL project are: Minervax ApS (Denmark); Technical University of Denmark (Denmark); and Bioneer A/S (Denmark).
Dr. Alcide Barberis, Head of Research and Collaborations at Telormedix, has been appointed as the project’s scientific coordinator.
Dr. Barberis commented: “We are delighted to have received funding from the Eurostars Programme to coordinate the LIPODEL project. We intend for this to be the beginning of a rewarding collaboration with Minervax, Technical University of Denmark and Bioneer- we look forward to working with them to improve immunotherapy and develop effective vaccine candidates for Group B Streptococcus.”
Dr. Johanna Holldack, CEO at Telormedix, added: “These Eurostars awards are much sought after and we consider it prestigious to be awarded one for our novel and promising adjuvant program."
The Eurostars Programme is the European funding and support programme specifically dedicated to stimulating international collaborative research and innovation projects of small and medium enterprises. For further information on the Eurostars Programme, please visit: www.eurostars-eureka.eu
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.